IGEA announces changes in its supervisory board
This press release complements today’s announcement “IGEA calls extraordinary general meeting” to be viewed here.
Hoofddorp, the Netherlands, 3 December 2019. IGEA Pharma N.V. (SIX: IGPH) today announced changes in its supervisory board. As announced today by separate press release, IGEA proposes to its shareholders to amend the articles of association by introducing a one-tier board structure with executive and non-executive directors. The current supervisory board will be abolished as a corporate body in connection with this proposed amendment. Giovanni Ferrario and Mark de Simone, chairman and member, respectively, of the current supervisory board, will stand for election as non-executive directors. Federico Bazzoni and Flavio Peralda resigned and will no longer serve as directors.
Together with Giovanni Ferrario and Mark de Simone, Mr. Mario Patrocollo, Mr. Camillo Ricordi and Mr. Barth A. Green were nominated for election as non-executive directors of IGEA at the upcoming extraordinary general meeting on 8 January 2020.
“The adoption of a one-tier solution is an international recognized standard that will make our processes more efficient and functional. But my satisfaction is for having Mario, Camillo and Barth with us. Their amazing professional background will for sure contribute to the further development of our business” said Giovanni Ferrario, chairman of the supervisory board of IGEA.
The CVs of Mario Patrocollo, Camillo Ricordi and Barth A. Green are available here:
IGEA is a group focused on health-tech products and devices operating on the US market. IGEA commercialize Alz1, an at-home lab testing kit to measure non ceruloplasmin bound copper (generally defined as “free” copper) in the bloodstream and Alz1 Tab, a natural dietary supplement designed to reduce and control heavy metal contents in the bloodstream. “Free” copper is a risk factor associated with Alzheimer’s and diabetes type II. Monitoring and normalizing “free” copper can contribute to reduce the risk of Alzheimer’s and diabetes type II respectively.
IGEA is listed on the SIX Swiss Exchange under the ticker IGPH and is headquartered in Hoofddorp, the Netherlands.
For further information, please visit the IGEA website at https://www.igeapharma.nl/
IGEA Pharma N.V. Investor Relations: https://www.igeapharma.nl/investors-relations/
Vincenzo Moccia, CEO
Tel +31 23 568 94 94/ +39 340 583 09 33
Patrick Pozzorini, CFO
Tel +31 23 568 94 94/ +41 79 314 41 43
IGEA Pharma N.V.
Siriusdreef 17, 2123 WT Hoofddorp, the Netherlands
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN.
This document constitutes neither an offer to buy nor to subscribe securities and neither this document nor any part of it should form the basis of any investment decision in IGEA.
The information contained in this press release has been carefully prepared. However, IGEA bears and assumes no liability of whatever kind for the correctness and completeness of the information provided herein. IGEA does not assume an obligation of whatever kind to update or correct information contained in this press release whether as a result of new information, future events or for other reasons.
This publication may contain specific forward-looking statements and assessments or intentions concerning IGEA and its business. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of IGEA and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties, readers should not rely on forward-looking statements. IGEA assumes no responsibility to update forward-looking statements or to adapt them to future events or developments, except as may be required by law.
Documents for download:
Press release in PDF